Skip to content

ADMA Biologics

US · ADMA #2705 by market cap Listed 1970
13.17 -0.17 -1.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.3 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
89.89% -1.35pp
Institutions
389 +13
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund62.35%
Hedge Fund17.92%
Public Company3.96%
Individual/Insider1.89%
Government Pension Fund1.46%
Family Office/Trust1.46%
Private Company1.38%
VC/PE Fund1.12%
Other8.37%

Top holders as of 2026-09-30

BlackRock 16.82% · 37.31M sh
State Street Global Advisors 6.16% · 13.68M sh
Vanguard Capital Management, LLC 4.27% · 9.47M sh
Rubric Capital Management LP 4.21% · 9.34M sh
Vanguard Portfolio Management, LLC 4.15% · 9.21M sh
Capital Research 3.94% · 8.75M sh
First Trust Advisors L.P. 3.52% · 7.80M sh
Geode Capital Management, LLC 2.67% · 5.92M sh
Caligan Partners, LP 2.58% · 5.73M sh
D. E. Shaw & Co., L.P. 2.38% · 5.27M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 23 buys · 25 sells

NameRoleStake
Adam Grossman Chief Executive Officer 1.31%
Jerrold Grossman Co-Founder & Vice Chairman of the Board 0.25%
Young Kwon Independent Director 0.11%
Lawrence Guiheen Independent Director 0.08%
Kaitlin Kestenberg COO & Senior VP of Compliance 0.07%
Steven Elms Independent Chairperson 0.04%
Alison Finger Independent Director 0.02%
Eduardo Salas Independent Director 0.00%
Brad Tade Former Consultant 0.00%
P. Terence Kohler Chief Financial Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-04 Adam Grossman Chief Executive Officer Open Market Disposition -42,000 $12.00
2026-11-04 Adam Grossman Chief Executive Officer Derivative Exercise and Sale -105,000 $5.40–12.00
2026-07-23 Kaitlin Kestenberg COO & Senior VP of Compliance Sale to Issuer -3,177 $8.37
2026-07-15 P. Terence Kohler Chief Financial Officer Other Acquisition +85,130 --
2026-07-15 P. Terence Kohler Chief Financial Officer Other Derivative Acquisition +136,363 $8.81
2026-05-26 Jerrold Grossman Co-Founder & Vice Chairman of the Board Open Market Acquisition +6,400 $7.91
2026-05-11 Jerrold Grossman Co-Founder & Vice Chairman of the Board Open Market Acquisition +12,500 $8.01
2026-05-10 Jerrold Grossman Co-Founder & Vice Chairman of the Board Open Market Acquisition +12,500 $8.01
2026-03-31 Kaitlin Kestenberg COO & Senior VP of Compliance Sale to Issuer -20,362 $9.11
2026-03-16 Lawrence Guiheen Independent Director Derivative Exercise and Sale -30,000 --
2026-03-16 Lawrence Guiheen Independent Director Other Acquisition +30,000 --
2026-03-15 Adam Grossman Chief Executive Officer Automatic Disposition -6,000 $15.16
2026-03-15 Adam Grossman Chief Executive Officer Derivative Exercise and Sale -15,000 $5.40–15.16
2026-03-09 Brad Tade Former Consultant Intent to Sell (Form 144) -50,026 $15.81
2026-03-08 Kaitlin Kestenberg COO & Senior VP of Compliance Other Disposition -91,266 --
2026-03-08 Kaitlin Kestenberg COO & Senior VP of Compliance Derivative Exercise and Sale -10,096 $1.55–15.63
2026-03-06 Adam Grossman Chief Executive Officer Sale to Issuer -85,951 $15.39
2026-03-06 Kaitlin Kestenberg COO & Senior VP of Compliance Sale to Issuer -14,294 $15.39
2026-03-05 Aisling Capital Management LP -- Open Market Acquisition +14,000 $15.39–15.67
2026-02-25 P. Terence Kohler Chief Financial Officer Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ADMA Biologics discussion 0 comments

Add a comment